v3.26.3
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CONTINGENTLY REDEEMABLE NONCONTROLLING INTEREST AND EQUITY - USD ($)
$ in Millions
Total
Series C Preferred Stock
Sempra shareholders' equity
Sempra shareholders' equity
Series C Preferred Stock
Preferred stock
Common stock
Retained earnings
Retained earnings
Series C Preferred Stock
AOCI
NCI
CRNCI                    
Contributions from CRNCI $ 3,166                  
Investor equity subscription 76                  
Allocation of interests (1,309)                  
Ending balance at Sep. 30, 2025 1,933                  
Beginning Balance at Dec. 31, 2024 37,788   $ 31,222   $ 889 $ 13,520 $ 16,979   $ (166) $ 6,566
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Net income 1,588   1,485       1,485     103
Other comprehensive income (loss) (51)   (46)           (46) (5)
Share-based compensation expense 25   25     25        
Dividends declared:                    
Preferred dividends   $ (29)   $ (29)       $ (29)    
Common stock dividends (1,262)   (1,262)       (1,262)      
Redemption of preferred stock (900)   (900)   (900)          
Preferred deemed dividends of subsidiary 0                  
Preferred deemed dividends 0   0   11   (11)      
Preferred dividends of subsidiary (1)   (1)       (1)      
Issuances of common stock 65   65     65        
Repurchases of common stock (58)   (58)     (58)        
CRNCI and NCI activities:                    
Investor equity subscription 25   16     16       9
Allocation of interests 1,090   635     635       455
Contributions from NCI 137                 137
Distributions to NCI (131)                 (131)
Ending balance at Sep. 30, 2025 $ 38,286   31,152   0 14,203 17,161   (212) 7,134
CRNCI and NCI activities:                    
Dividends declared per share of common stock (in dollars per share) $ 1.94                  
Contributions from CRNCI $ 3,166                  
Investor equity subscription 76                  
Allocation of interests (1,309)                  
Ending balance at Sep. 30, 2025 1,933                  
Beginning Balance at Jun. 30, 2025 38,296   31,697   889 13,518 17,505   (215) 6,599
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Net income 150   95       95     55
Other comprehensive income (loss) 5   3           3 2
Share-based compensation expense 14   14     14        
Dividends declared:                    
Preferred dividends   $ (7)   $ (7)       $ (7)    
Common stock dividends (421)   (421)       (421)      
Redemption of preferred stock (900)   (900)   (900)          
Preferred deemed dividends of subsidiary 0                  
Preferred deemed dividends 0   0   11   (11)      
Issuances of common stock 20   20     20        
CRNCI and NCI activities:                    
Investor equity subscription 25   16     16       9
Allocation of interests 1,090   635     635       455
Contributions from NCI 54                 54
Distributions to NCI (40)                 (40)
Ending balance at Sep. 30, 2025 $ 38,286   31,152   0 14,203 17,161   (212) 7,134
CRNCI and NCI activities:                    
Dividends declared per share of common stock (in dollars per share) $ 0.65                  
Beginning balance at Dec. 31, 2025 [1] $ 3,206                  
CRNCI                    
Net income 10                  
Allocation of interests 176                  
Ending balance at Sep. 30, 2026 3,392                  
Beginning Balance at Dec. 31, 2025 38,793 [1]   31,594   0 14,699 17,092   (197) 7,199
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Net income 3,196   2,717       2,717     479
Net income 3,206                  
Other comprehensive income (loss) 279   251           251 28
Share-based compensation expense 66   66     66        
Dividends declared:                    
Common stock dividends (1,289)   (1,289)       (1,289)      
Preferred deemed dividends of subsidiary (6)   (6)       (6)      
Preferred dividends of subsidiary (1)   (1)       (1)      
Issuances of common stock 72   72     72        
Repurchases of common stock (21)   (21)     (21)        
CRNCI and NCI activities:                    
Allocation of interests (176)   (56)     (56)       (120)
Purchase of NCI (20)                 (20)
Contributions from NCI 97                 97
Distributions to NCI (206)                 (206)
Ending balance at Sep. 30, 2026 $ 40,784   33,327   0 14,760 18,513   54 7,457
CRNCI and NCI activities:                    
Dividends declared per share of common stock (in dollars per share) $ 1.97                  
Beginning balance at Jun. 30, 2026 $ 3,308                  
CRNCI                    
Allocation of interests 84                  
Ending balance at Sep. 30, 2026 3,392                  
Beginning Balance at Jun. 30, 2026 39,998   32,685   0 14,763 18,066   (144) 7,313
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Net income 1,114   883       883     231
Net income 1,114                  
Other comprehensive income (loss) 221   198           198 23
Share-based compensation expense 22   22     22        
Dividends declared:                    
Common stock dividends (430)   (430)       (430)      
Preferred deemed dividends of subsidiary (6)   (6)       (6)      
Issuances of common stock 17   17     17        
CRNCI and NCI activities:                    
Allocation of interests (84)   (42)     (42)       (42)
Purchase of NCI (20)                 (20)
Contributions from NCI 23                 23
Distributions to NCI (71)                 (71)
Ending balance at Sep. 30, 2026 $ 40,784   $ 33,327   $ 0 $ 14,760 $ 18,513   $ 54 $ 7,457
CRNCI and NCI activities:                    
Dividends declared per share of common stock (in dollars per share) $ 0.65                  
[1] Derived from audited financial statements.